Budesonide Market to Witness Significant Growth of USD $12.95 Billion with 6% CAGR by 2029

 Get 20% Off Market Intelligence Reports With Code ONLINE20 — Track Global Tariffs, Economic Shifts, and Sector Transformations

 

 What Is the Growth Potential of the Budesonide Market in the Next Decade?
 The budesonide market size has grown strongly in recent years. It will grow from $9.72 billion in 2024 to $10.26 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to the rising prevalence of respiratory diseases, increased awareness about inhaled corticosteroids, the introduction of budesonide-based combination therapies, the expansion of healthcare access and infrastructures, and the adoption of budesonide for off-label use in inflammatory bowel diseases.
 
 The budesonide market size is expected to see strong growth in the next few years. It will grow to $12.95 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to growing demand for effective treatments, development of novel drug delivery systems, increasing use of budesonide, rising geriatric population prone to asthma, and expansion of generic budesonide products. Major trends in the forecast period include the adoption of biologics and biosimilars, advancements in drug delivery systems, regulatory approvals for new formulations, the development of novel drug delivery systems, and technological development.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=21121&type=smp
 
 What Are the Major Drivers Influencing the Budesonide Market?
 The increase in the prevalence of respiratory diseases is expected to propel the growth of the budesonide market going forward. Respiratory diseases refer to medical diseases that affect the organs and tissues that regulate gas exchange in air-breathing animals. The increase in the prevalence of respiratory diseases is due to rising air pollution, particularly exposure to particulate matter and allergens, which has a major impact on the prevalence of asthma and chronic obstructive lung disease. Budesonide is used in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) to reduce inflammation, improve airflow, and prevent symptoms such as wheezing and shortness of breath. For instance, in May 2024, according to the National Center for Health Statistics (NCHS), a US-based health statistics agency, the prevalence of current asthma among adults aged 18 and over in the United States increased from 8.4% in 2021 to 8.7% in 2022. Additionally, the incidence of asthma episodes in the past 12 months for adults in the same age group rose from 3.3% in 2021 to 3.7% in 2022. Therefore, the increase in the prevalence of respiratory diseases will drive the growth of the budesonide market.
 
 Which Segment Holds the Largest Share in the Budesonide Market?
 The budesonide market covered in this report is segmented — 
 
 1) By Type: Inhalation Powder, Aerosols, Injectable Suspension, Tablets And Capsules
 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
 3) By Application: Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Respiratory Disease Treatment, Other Applications
 
 Subsegments:
 1) By Inhalation Powder: Dry Powder Inhalers (DPI), Soft Mist Inhalers (SMI) 
 2) By Aerosols: Metered-Dose Inhalers (MDI), Breath-Activated Inhalers 
 3) By Injectable Suspension: Pre-filled Syringes, Vials 
 4) By Tablets And Capsules: Oral Tablets, Oral Capsules
 
 What Are the Major Trends Impacting the Budesonide Market?
 Major companies operating in the budesonide market are focusing on advancements in respiratory treatment, such as oral therapy, enhancing patient convenience, improving treatment adherence, and expanding therapeutic options for managing asthma and other respiratory conditions. Oral therapy budesonide is a formulation of budesonide taken by mouth, primarily used to treat inflammatory conditions. For instance, in February 2024, Takeda Pharmaceuticals, a Japan-based pharmaceutical company, announced that the Food and Drug Administration (FDA), a US-based federal agency, has authorized EOHILIA, a budesonide oral suspension, as the first and only FDA-approved oral medication for patients aged 11 and above with eosinophilic esophagitis (EoE). Additionally, the FDA approved EOHILIA 2 mg twice daily based on effectiveness and safety data from two multicenter, randomized, double-blind, parallel-group, placebo-controlled 12-week investigations in individuals aged 11 to 56 with EoE.
 
 Which Major Companies Are Operating in the Budesonide Market?
 Major companies operating in the budesonide market are AstraZeneca AB, Novartis AG, Takeda Pharmaceuticals Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz AG, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Limited, Orion Corporation, Salix Pharmaceuticals Inc., Synmosa Biopharma Corporation, Cosmo Pharmaceuticals N.V., Skyepharma Holdings Inc., Manus Aktteva Biopharma LLP, Cennet Biopharma Private Limited, Santarus Inc., SiNi Pharma Private Limited, Shanghai Sine Promod Pharmaceutical Co. Ltd. 
 
 Get the full budesonide market report here:
 https://www.thebusinessresearchcompany.com/report/budesonide-global-market-report
 
 Which Region Is Expected to Lead the Budesonide Market by 2029?
 North America was the largest region in the budesonide market in 2024. The regions covered in the budesonide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company